Jefferies initiates Mentari Therapeutics stock with buy rating on migraine pipeline

Jefferies initiated coverage on Mentari Therapeutics (NASDAQ:MTRI) with a buy rating and a $30.00 price target, citing its migraine prevention drug pipeline. The stock trades at $16, 31% below its 52-week high. The company expects Phase I data for MT-001 and MT-002 in 2027. MTRI has $450 million in cash, providing runway into 2029.

Original reporting
Published Nov 10, 2026, 6:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 6:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MTRI
Bullish
high confidence
Mentioned
$MTRI
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MTRIBullishMed
01

Why it matters

The new coverage could trigger a short‑term rally, but long‑term performance hinges on trial outcomes.

02

Market read

Analyst initiation provides fresh actionable insight for traders.

03

What to watch

Cash runway is strong, but valuation assumes successful later‑stage trials.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Mentari Therapeutics is a small‑cap biotech developing PACAP‑based migraine preventatives.

Company-level read

Ticker impact

$MTRIBullishHigh confidence
Context

Jefferies initiates coverage on Mentari Therapeutics with a buy rating and a $30 price target, highlighting its migraine pipeline.

Expected impact

upward pressure as investors price in the new buy rating and target.

Evidence & confidence

The initiation of coverage with a buy rating is a fresh catalyst that can attract new capital into the stock.

Market effects

May lift sentiment in the biotech migraine‑therapy niche.

Limited to US biotech investors.

Minor, confined to niche therapeutic area.

Counterpoint

The pipeline is early‑stage; investors may remain cautious until Phase II data.

Key entities

  • Jefferies

    Initiated coverage with a buy rating.

  • Mentari Therapeutics

    Biotech developing migraine treatments.

Related articles

$UBERMed

Uber Becomes McDonald’s “Preferred Delivery Partner” in 14 Markets as Its DoorDash Fight Widens

McDonald's named Uber its preferred delivery partner for orders in its app, expanding a partnership across 14 markets. The deal, part of a multi-year agreement, includes Uber handling McDonald's app orders and integrating rewards. McDonald's delivery business generates over $20 billion annually. Uber reported $9.8 billion in free cash flow in 2025. DoorDash remains the market leader with 59% of delivery-app spending, but Uber is gaining ground with high-profile partnerships.